文献速递消化道肿瘤与早癌

利用类器官构建人胃癌模型

Human gastric cancer modelling using organoids.
PubMed 文献 · Gut · 2018-04-27

该研究建立人胃癌类器官培养体系,对4例样本进行深入分析,并构建携带分子亚型特异性改变的小鼠胃癌类器官。类器官对5-氟尿嘧啶、奥沙利铂、伊立替康、表柔比星和多西他赛呈现差异化反应,全基因组测序揭示了与微卫星不稳定、基因组稳定和染色体不稳定亚型对应的突变谱,并可针对ERBB2改变使用曲妥珠单抗、针对CDKN2A缺失使用帕博西尼进行靶向治疗。

要点

  • 建立20例人胃癌类器官培养,选取4例进行深入分析。
  • 类器官对5-氟尿嘧啶、奥沙利铂、伊立替康、表柔比星和多西他赛反应存在差异。
  • 全基因组测序突变谱对应微卫星不稳定、基因组稳定和染色体不稳定亚型。

核心结论

  • 研究建立了模拟人胃癌典型特征和改变通路的人和小鼠胃癌类器官,成功干预激活通路显示其作为治疗反应检测活体生物标志物的潜在用途。

研究设计与样本

  • 建立人胃癌类器官培养,根据分子谱分类样本并检测对常规化疗的反应,根据特定可成药突变进行靶向治疗。
  • 构建携带分子亚型特异性改变的小鼠胃癌类器官培养。

主要发现

  • 建立20例人胃癌类器官培养,选取4例进行全面的深入分析。
  • 类器官表现出不同的生长特性和形态,免疫组化显示与对应原发组织相似的特征。
  • 观察到对5-氟尿嘧啶、奥沙利铂、伊立替康、表柔比星和多西他赛治疗的反应存在差异。
  • 全基因组测序揭示的突变谱与先前鉴定的微卫星不稳定、基因组稳定和染色体不稳定胃癌亚型相对应。
  • 突变 landscape 允许针对ERBB2改变使用曲妥珠单抗、针对CDKN2A缺失使用帕博西尼进行靶向治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Gastric cancer is the second leading cause of cancer-related deaths and the fifth most common malignancy worldwide. In this study, human and mouse gastric cancer organoids were generated to model the disease and perform drug testing to delineate treatment strategies. DESIGN: Human gastric cancer organoid cultures were established, samples classified according to their molecular profile and their response to conventional chemotherapeutics tested. Targeted treatment was performed according to specific druggable mutations. Mouse gastric cancer organoid cultures were generated carrying molecular subtype-specific alterations. RESULTS: Twenty human gastric cancer organoid cultures were established and four selected for a comprehensive in-depth analysis. Organoids demonstrated divergent growth characteristics and morphologies. Immunohistochemistry showed similar characteristics to the corresponding primary tissue. A divergent response to 5-fluoruracil, oxaliplatin, irinotecan, epirubicin and docetaxel treatment was observed. Whole genome sequencing revealed a mutational spectrum that corresponded to the previously identified microsatellite instable, genomic stable and chromosomal instable subtypes of gastric cancer. The mutational landscape allowed targeted therapy with trastuzumab for ERBB2 alterations and palbociclib for CDKN2A loss. Mouse cancer organoids carrying Kras and Tp53 or Apc and Cdh1 mutations were characterised and serve as model system to study the signalling of induced pathways. CONCLUSION: We generated human and mouse gastric cancer organoids modelling typical characteristics and altered pathways of human gastric cancer. Successful interference with activated pathways demonstrates their potential usefulness as living biomarkers for therapy response testing.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Seidlitz T, Merker SR, Rothe A, et al. Human gastric cancer modelling using organoids. Gut. 2018. PMID: 29703791. doi:10.1136/gutjnl-2017-314549

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。